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NOTEWORTHY CASES
ANTI–3-HYDROXY-3-METHYLGLUTARYL-
COENZYME A REDUCTASE
AUTOANTIBODY-POSITIVE NECROTIZING
AUTOIMMUNE MYOPATHY WITH
DERMATOMYOSITIS-LIKE ERUPTION
A 47 year-old man presented with a 4-week history of
myalgia, dysarthria, dysphagia, and generalized weakness
after having been receiving atorvastatin for 1 year. On
examination, he had a heliotrope rash and nonpruritic,
erythematous macular rashes that were present around
the neck, upper chest, and extensor surfaces of the
interphalangeal and metacarpophalangeal joints. No nail
findings such as telangiectasia or ragged cuticles were
seen. Neurological examination revealed flaccid dysarth-
ria associated with palatal weakness and mild weakness
in the orbicularis oculi and orbicularis oris muscles.
Motor strength was graded as follows (Medical Research
Council [MRC] scale): neck flexors, 3; neck extensors, 4;
shoulder abductors, 4; elbow flexors, 4; elbow extensors,
5; wrist extensors, 3; wrist flexors, 4; finger extensors, 3;
first dorsal interossei, 2; hip flexors, 4; knee extensors, 4;
knee flexors, 4; ankle dorsiflexors, 3; and plantar flexors,
4. Creatine kinase (CK) was elevated, with a peak level
of 37,527 U/L (normal range, 30–220 U/L). Needle
electromyography showed short-duration and small-
amplitude motor unit potentials, fibrillation potentials,
and positive-wave discharges in the proximal and distal
limb muscles. Serum testing for the autoantibodies Jo-1,
PM-SCL, SRP, and NXP2 were negative. A right rectus
femoris muscle biopsy revealed muscle fiber size variabil-
ity, mild fiber necrosis, and mild mononuclear infiltra-
tion without perifascicular atrophy. C5b9 staining for
membrane attack complex was unremarkable, and major
histocompatibility complex class I staining revealed a dif-
fuse sarcolemmal overexpression (Fig. 1). A request for
a biopsy of a distal limb muscle with greater weakness
was declined by the patient. Serum anti-3-hydroxy-3-
methylglutaryl-coenzyme A reductase (anti-HMGCR)
antibody exceeded 200 units (normal 20 units) on
enzyme-linked immunosorbent assay (RDL Reference
Laboratory, Los Angles, CA) and was also positive by
immunoprecipitation by our own laboratory, confirming
the diagnosis of statin-associated necrotizing auto-
immune myopathy (NAM). Treatment was initiated with
intravenous methylprednisolone 1 g per day for 5 days,
followed by intravenous immunoglobulin (IVIG) 0.4 g/
kg/day for 5 days and oral prednisone 80mg per day.
However, muscle weakness persisted, and CK remained
highly elevated in the range of 19,000 to 34,000 U/L.
Subsequent treatment with plasmapheresis for 5 sessions
led to a reduction of CK level to 6,481 U/L. The
patient’s muscle strength returned to normal in all
muscles except for the neck flexors, shoulder abductors,
wrist extensors, and ankle dorsiflexors, which were
graded as MRC 4. Maintenance plasmapheresis 2 days
per month was continued. Mycophenolate mofetil was
initiated at 1,000mg twice per day, and prednisone dose
was tapered down to 20mg per day over the next 4
months. At month 5, the heliotrope and other skin
rashes had resolved with a near complete recovery of
limb strength and a CK level of 1,427 U/L.
NAM can be a rare complication of statin usage that
is associated with anti-HMGCR antibodies and is charac-
terized by histopathological features of muscle fiber
necrosis with minimal to no inflammation.1–3 Patients
typically present with various degrees of symmetrical
proximal limb weakness and prominent CK elevation
that often exceeds 6,000 U/L.1 Treatment usually con-
sists of corticosteroids, steroid sparing agents, or IVIG.
Most patients require combination therapy and do not
respond to corticosteroids alone.1,4 The history of statin
use, prominent CK elevation, muscle fiber necrosis with
minimal inflammation, and high-titer anti-HMGCR anti-
bodies confirmed the diagnosis of anti-HMGCR associ-
ated NAM in our patient.
Our patient showed a heliotrope rash and Gottron’s
sign, cutaneous manifestations that are considered
pathognomonic for dermatomyositis. Typical histopatho-
logic features of dermatomyosistis such as perifascicular
atrophy and prominent inflammation were not observed.
Although anti-HMGCR antibody was not detected in 33
adult cases of dermatomyositis, it has been found in rare
cases (0.8%) of juvenile dermatomyositis.2,5 Our case
report raises the possibility of anti-HMGCR myopathy
presenting with dermatomyositis-like features in adult
patients. Recently, Lavian et al.6 described a patient who
developed anti-HMGCR antibody-positive NAM with
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similar dermatomyositis-like features. Just as with our
patient, theirs demonstrated heliotrope rash and Got-
tron’s signs, significant elevation of CK (3,000–20,000
U/L), and lack of inflammation or perifascicular atro-
phy on muscle biopsy. Their patient responded well to
high-dose prednisone, methotrexate, and monthly IVIG.
The common features shared by these 2 patients show
the overlapping characteristics of anti-HMGCR antibody-
positive NAM with dermatomyositis and the value of
detecting serologic markers such as anti-HMGCR
antibody.
Our patient also had a few additional unique fea-
tures. Severe distal limb weakness was the predominant
manifestation, although only mild proximal weakness
was observed. Significant distal limb muscle weakness is
rarely encountered in statin-associated NAM but was
described in 3 cases of juvenile dermatomyositis with
positive anti-HMGCR antibodies.5 Finally, limited cases
of NAM responding to plasmapheresis have been
described, 1 of which included 2 patients with anti-
HMGCR myopathy.7 The use of plasmapheresis in our
patient, who had minimal response to corticosteroids
and IVIG, led to significant clinical and laboratory
improvements, suggesting its role as a potential thera-
peutic option in patients with NAM.
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DUCHENNE MUSCULAR DYSTROPHY
CAUSED BY A NOVEL DEEP INTRONIC DMD
MUTATION
Duchenne muscular dystrophy (DMD) is an X-linked
muscular dystrophy affecting up to 1:3,500 male births.1
The disease is caused by mutations in the DMD gene
that encodes the protein dystrophin. Most patients with
DMD harbor an out-of-frame deletion, duplication, or
nonsense mutation.2 Rarely, splice site mutations have
been reported to cause DMD.3 We report 2 siblings with
DMD due to a novel intronic deletion.
CASE DESCRIPTION
The proband presented at 3 years of age because of
concerns about poor social interactions, and he met cri-
FIGURE 1. Muscle biopsy. (A) Rare necrotic fibers on hematoxylin and eosin staining (3400). (B) Diffuse sarcolemmal overexpression
of major histocompatibility complex I (3200).
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